

**From:** [Riggins, Cindy](#)  
**To:** [Giordano, Erica](#); [Patel, Manisha](#)  
**Cc:** [Ahmed, Narin](#)  
**Subject:** RE: BL 125646 - Vector Final Container Information Request  
**Date:** Friday, March 24, 2017 9:59:26 AM  
**Attachments:** [7008911\\_ANSW\\_MC\\_840\\_7.pdf](#)  
[DMF 11820 LoA \(b\) \(4\) 21-Mar-2017.pdf](#)  
[DMF 012456 LoA \(b\) \(4\) 20-Mar-2017.pdf](#)  
[DMF 016769 LoA \(b\) \(4\) 20-Mar-2017.pdf](#)  
[TRPT-16-026 L&E Risk Assessment for the Adherent CTL019 VS & VP.PDF](#)  
**Sensitivity:** Confidential

---

Dear Erica,

Attached are the responses to the Vector Final Container information request received on March 15, 2017. There are a total of 5 documents: one ANSW document and 4 appendices. We will follow up with a BLA amendment through the gateway of these documents.

Take care,

Cindy

---

**From:** Giordano, Erica [mailto:Erica.Giordano@fda.hhs.gov]  
**Sent:** Wednesday, March 15, 2017 9:01 AM  
**To:** Patel, Manisha  
**Cc:** Riggins, Cindy; Ahmed, Narin  
**Subject:** BL 125646 - Vector Final Container Information Request  
**Sensitivity:** Confidential

Good morning,

For the vector product container closure system as described in section 3.2.S.6 (vector), please address the following and provide a response by noon on March 24, 2017:

Please provide detailed information (such as compatibility, toxicity and biological tests) regarding the components of the vector DP primary container closure system (the (b) (4) [REDACTED]). This information may be provided by cross-reference to drug master files, if appropriate.

Section 3.2.S.6.2.1.1 (vector, container closure system) states that the vector final container is a (b) (4) [REDACTED], but 3.2.S.2.5.7 (vector, extractable and leachable assessment) states that the vector final container is a (b) (4) [REDACTED]. Please explain this discrepancy, and please submit the extractable and leachable assessment that is summarized in 3.2.S.2.5.7.

Please confirm that the (b) (4) [REDACTED] used for the (b) (4) [REDACTED] stability study is intended for use as final vector product storage. If not (as per discrepancy above), please provide justification for not repeating the CCI study.

Please provide correlation of the container closure integrity study with media to the vector product.

Please provide a detailed summary of the (b) (4) [REDACTED] method validation which should include information on (b) (4) [REDACTED] stability in the presence of media, method sensitivity and scientific rationale for a (b) (4) [REDACTED].

Please consider adding CCIT at product expiry (b) (4) stability test point) as part of the stability program for the vector product.

Please confirm receipt of this request.

*Thank you,*

**Erica Giordano**

*Regulatory Project Manager*

Center for Biologics Evaluation and Research

Office of Tissues and Advanced Therapies

U.S. Food and Drug Administration

Tel: 240-402-8298

[Erica.Giordano@fda.hhs.gov](mailto:Erica.Giordano@fda.hhs.gov)



"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."